Investment Rating - The report maintains an "Accumulate" investment rating for the company, indicating a projected relative increase of 5% to 15% compared to the CSI 300 index over the next six months [8][16]. Core Views - The company's performance is under short-term pressure, with total revenue for 2024 at 391 million yuan, down 26.77% year-on-year, and a net profit of 50 million yuan, down 36.49% year-on-year [7]. - The sales of corn seeds are under pressure, with revenue from corn seeds at 196 million yuan, a decrease of 42.05% year-on-year, while wheat seed revenue increased by 5.52% [7]. - The company continues to enhance its R&D capabilities, with a 17.98% year-on-year increase in R&D expenses, which is crucial for maintaining its competitive edge in the industry [7]. - The company’s gross margin for 2024 is reported at 27.86%, down 4.23 percentage points year-on-year, while the net margin is at 12.89%, down 1.98 percentage points year-on-year [7]. - The commercialization of biotechnology breeding is progressing steadily, with significant policy support expected to enhance profitability and market share for industry players [8]. Summary by Sections Financial Performance - In Q1 2025, the company reported a revenue of 19 million yuan, down 45.25% year-on-year, and a net profit of -4.48 million yuan, indicating a shift from profit to loss [7]. - The company’s total revenue for 2024 was 391 million yuan, with a significant decline in net profit and cash flow [7][9]. Product Performance - Corn seed sales have been particularly affected, with a revenue drop of 42.05% year-on-year, while wheat seed sales showed a modest increase [7]. - The company’s core products, including various corn and wheat varieties, continue to receive recognition and maintain competitive advantages in the market [7]. R&D and Competitive Position - The company has increased its R&D investment, which is essential for sustaining its market position and developing new products [7]. - Several of the company’s seed varieties have been recognized as leading products in their respective categories, indicating strong market presence [7]. Market Outlook - The report anticipates a gradual recovery in the industry, with projected net profits of 55 million yuan in 2025, 66 million yuan in 2026, and 77 million yuan in 2027 [8][9]. - The company is expected to remain within a reasonable valuation range compared to industry peers, with projected EPS of 0.33 yuan in 2025 and a PE ratio of 58.86 [8][9].
秋乐种业（831087）：2024年年报及2025年一季报点评：业绩短期承压，静待行业拐点